The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

Sainz-Cort, Alberto; Jiménez-Garrido, Daniel F.; Muñoz-Marrón, Elena; Viejo-Sobera, Raquel; Heeroma, Joost H.; Bouso, José Carlos

doi:10.1089/can.2022.0037

Cited by 3 publications

(2 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the potentially protective effects of CBD in this context require further investigation as we did not find a consistent effect of CBD co-administration on THC-induced psychosis-like symptoms. While earlier experimental studies included in our work were suggestive of protective effects of CBD, [33][34][35] two recent studies did not replicate these findings. 36,37 Interestingly, lower but significant rates of CAPS were also observed in placebo groups assessed as part of THC-challenge studies (% THC = 25% versus % placebo = 11%) and medicinal cannabis trials (% THC = 3% versus % placebo = 1%), highlighting that psychotic symptoms occur not only in the context of cannabis exposure.…”

Section: Rates Of Cannabis-associated Psychotic Symptomscontrasting

confidence: 69%

Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research

Schoeler,

Baldwin,

Martin

et al. 2024

Nat. Mental Health

View full text Add to dashboard Cite

Cannabis, one of the most widely used psychoactive substances worldwide, can give rise to acute cannabis-associated psychotic symptoms (CAPS). While distinct study designs have been used to examine CAPS, an overarching synthesis of the existing findings has not yet been carried forward. To that end, we quantitatively pooled the evidence on rates and predictors of CAPS (k = 162 studies, n = 210,283 cannabis-exposed individuals) as studied in (1) observational research, (2) experimental tetrahydrocannabinol (THC) studies, and (3) medicinal cannabis research. We found that rates of CAPS varied substantially across the study designs, given the high rates reported by observational and experimental research (19% and 21%, respectively) but not medicinal cannabis studies (2%). CAPS was predicted by THC administration (for example, single dose, Cohen’s d = 0.7), mental health liabilities (for example, bipolar disorder, d = 0.8), dopamine activity (d = 0.4), younger age (d = −0.2), and female gender (d = −0.09). Neither candidate genes (for example, COMT, AKT1) nor other demographic variables (for example, education) predicted CAPS in meta-analytical models. The results reinforce the need to more closely monitor adverse cannabis-related outcomes in vulnerable individuals as these individuals may benefit most from harm-reduction efforts.

show abstract

Section: Rates Of Cannabis-associated Psychotic Symptomscontrasting

confidence: 69%

Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research

Schoeler,

Baldwin,

Martin

et al. 2024

Nat. Mental Health

View full text Add to dashboard Cite

show abstract

“…57,67,68 On the other hand and in accordance with our results, a recently published trial evaluated the effects of vaporized CBD (130 mg) during the MET task in a naturalistic context but reported no significant effects compared with placebo. 69 Because this was the first study that evaluated changes in empathy with ayahuasca and CBD concomitant administration, the findings need to be replicated to become conclusive.…”

Section: Discussionmentioning

confidence: 98%

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers

Rossi

Rocha

Osório

et al. 2023

J Clin Psychopharmacol

View full text Add to dashboard Cite

BackgroundSerotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE.ProceduresSeventeen healthy volunteers participated in a 1-week preliminary parallel-arm, randomized controlled trial for 18 months. Volunteers received a placebo or 600 mg of oral CBD followed by oral ayahuasca (1 mL/kg) 90 minutes later. Primary outcomes included REFE and empathy tasks (coprimary outcome). Tasks were performed at baseline and 6.5 hours, 1 and 7 days after the interventions. Secondary outcome measures included subjective effects, tolerability, and biochemical assessments.ResultsSignificant reductions (all P values <0.05) only in reaction times were observed in the 2 tasks in both groups, without between-group differences. Furthermore, significant reductions in anxiety, sedation, cognitive deterioration, and discomfort were observed in both groups, without between-group differences. Ayahuasca, with or without CBD, was well tolerated, producing mainly nausea and gastrointestinal discomfort. No clinically significant effects were observed on cardiovascular measurements and liver enzymes.ConclusionsThere was no evidence of interactive effects between ayahuasca and CBD. The safety of separate and concomitant drug intake suggests that both drugs could be applied to clinical populations with anxiety disorders and in further trials with larger samples to confirm findings.

show abstract

Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis

Sainz-Cort,

Martín-Islas,

Oña

et al. 2023

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire–modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.

show abstract

The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

Cited by 3 publications

References 101 publications

Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research

Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers

Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis

Contact Info

Product

Resources

About